"TBSF" Human Immunoglobulin for Intravenous Use

Nazione: Australia

Lingua: inglese

Fonte: Department of Health (Therapeutic Goods Administration)

Principio attivo:

normal immunoglobulin, Quantity: 60 g/L

Commercializzato da:

CSL Behring Australia Pty Ltd

INN (Nome Internazionale):

normal immunoglobulin

Forma farmaceutica:

Injection, solution

Composizione:

Excipient Ingredients: maltose

Via di somministrazione:

Intravenous

Confezione:

50mL, 200mL

Classe:

Medicine Listed (Export Only)

Tipo di ricetta:

(S1) This Schedule is intentionally blank

Indicazioni terapeutiche:

TBSF Human Immunoglobulin for Intravenous Use is indicated for replacement IgG therapy in: * primary immunodeficiency (PID) * symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. TBSF Human Immunoglobulin for Intravenous Use is indicated for immunomodulatory therapy in: * Idiopathic Thrombocytopenic Purpura (ITP), in adults or children at high risk of bleeding or prior to surgery to correct the platelet count * allogeneic bone marrow transplantation * Kawasaki disease * Guillain-Barre Syndrome (GBS).

Dettagli prodotto:

Visual Identification: Clear, colourless solution; Container Type: Vial; Container Life Time: 3 Years; Container Temperature: Store at 2 to 8 degrees Celsius

Stato dell'autorizzazione:

Listed (Export Only)

Data dell'autorizzazione:

2006-03-01